Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BL B01D1

Next Previous
X
Search
Drug Profile

BL B01D1

Alternative Names: BL-B01D1

Latest Information Update: 04 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Baili Pharmaceutical; SystImmune
  • Developer Bristol-Myers Squibb; Sichuan Baili Pharmaceutical; SystImmune
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase III HER2 negative breast cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
  • Phase II Cervical cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Phase I Gastrointestinal cancer

Most Recent Events

  • 07 Aug 2024 Phase-III clinical trials in Small cell lung cancer (Second-line therapy or greater, Recurrent) in China (IV) (NCT06500026)
  • 02 Aug 2024 Phase-II clinical trials in Triple-negative-breast-cancer (Metastatic disease, Late-stage disease, Recurrent, Inoperable/Unresectable, First-line therapy) in China (IV) (NCT06471205)
  • 31 Jul 2024 Sichuan Baili Pharmaceutical initiates enrollment in a phase II trial for Non-small cell lung cancer (Late stage disease, Metastatic disease, Combination therapy) in China (IV, Infusion) (NCT06498986)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top